Oli is a senior associate in our Cambridge office and is part of the Corporate Technology team.
Oli advises a range of companies in the tech and life sciences sectors on a variety of corporate matters, including venture capital investments, fundraisings, M&A and joint ventures.
We advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.
Press releasevon Ross McNaughton und Oli Denne
Advising personal care brand, Wild, on its acquisition by Unilever
von Ed Chapman und Oli Denne
Shift Bioscience raises US$16 million seed funding
von Ross McNaughton und Oli Denne
von Bridget Winters
von Dr. Christian Frank, Licencié en droit (Paris II / Panthéon-Assas)
von mehreren Autoren
von mehreren Autoren
von Giles Crown
von Charlotte Peach und Giles Crown
von mehreren Autoren
von mehreren Autoren
von Colin McCall und Charlie Adams